Anaphylaxis/severe allergic reactions (vs EpiPen IM injection)(Phase 2)
Catalysts
— Q3 2026
— Q4 2026
Status note Lead candidate (intranasal epinephrine). Completed 12-patient pilot and 12-patient Phase 2 (PK in line with IM epinephrine). Additional Phase 2 in Canada launched Nov 2025 (50 healthy adults with allergic rhinitis vs EpiPen); additional Phase 2 evaluating self-administration planned Q2 2026; IND not yet filed.
NS001
Preclinical · ActiveModality: intranasal naloxone
Target opioid receptor
Indications
Not named in excerpts(Preclinical)
Status note Intranasal Naloxone development paused; company planning to pursue partnering opportunities for this program.
Status note Filing names intranasal atropine powder nasal spray for organophosphate poisoning as a program using the company's platform technology (tested with preclinical and in-vitro molecules).
Status note Filing names intranasal ondansetron powder nasal spray for intractable vomiting as a program using the company's platform technology.
Per-asset detail extracted from the 20-F filed 2026-03-25. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.